Drug.ob

[jiesen]

will be one to watch this week and over the next year or three, imo.

http://biz.yahoo.com/prnews/061114/to484.html?.v=8

0.05 EPS this quarter, revenues increased 41%. BV is over 0.50 and yet the price is just 0.54 right now.

[Websman]

will be one to watch this week and over the next year or three, imo.

http://biz.yahoo.com/prnews/061114/to484.html?.v=8

0.05 EPS this quarter, revenues increased 41%. BV is over 0.50 and yet the price is just 0.54 right now.
Even a better deal now that it's at .49. Short term looks bearish, but long term potential looks good. I'll put this one on my watchlist for a possible pullback buy.

[Lyehopper]

Even a better deal now that it's at .49. Short term looks bearish, but long term potential looks good. I'll put this one on my watchlist for a possible pullback buy.
Somebody got a 50%+ discount at the open today @ $0.21.... Sucka recovered pronto though.

[Lyehopper]

will be one to watch this week and over the next year or three, imo.

http://biz.yahoo.com/prnews/061114/to484.html?.v=8

0.05 EPS this quarter, revenues increased 41%. BV is over 0.50 and yet the price is just 0.54 right now.
Tell me more.... What is 7ACA?

[jiesen]

Tell me more.... What is 7ACA?

http://www.dragonpharma.com/products.asp?pn=2

7-ACA and clavulanic acid are the two products in Dragon's Chemical Division, and make up the bulk of the company's sales.

7-ACA is an intermediate in the production of Cephalosporin. They can make 600 tons of it each year.

They also make 50 tons of clavulanic acid per year, and they are the only commercial producers in China.

They're ramping up and making more of it each year... the biggest concern here would be what they're going to do with the debt overhang. I think they're planning to issue a bunch of stock to get rid of it, and that's why the price is depressed. But once that's taken care of, the stock should rise along with the sales.

I own this one partly because it looks cheap for its potential in the long-term, but also because it's good exposure to the Chinese market.

[jiesen]

Somebody got a 50%+ discount at the open today @ $0.21.... Sucka recovered pronto though.

yeah, I know. I saw it at 0.38 this morning and was really tempted to buy some more of it, but I hesitated and next thing I knew it was back up to 0.49. Now I'm kicking myself for not buying it there when I knew it was a steal, but I'd rather be too slow and miss some opportunites, than jump the gun and get burned.

[jiesen]

will be one to watch this week and over the next year or three, imo.

http://biz.yahoo.com/prnews/061114/to484.html?.v=8

0.05 EPS this quarter, revenues increased 41%. BV is over 0.50 and yet the price is just 0.54 right now.

DRUG.OB is now a double from last year's price, or a triple if you held out for 0.4 or lower. Where's it headed now?

http://finance.yahoo.com/q/bc?s=DRUG.OB&t=2y&l=on&z=m&q=l&c=

I'm still holding my same 1% position in this I've had for years now.

[Websman]

DRUG.OB is at .75 today. Looks like it was a good buy at .48.

[jiesen]

Something's up with DRUG.OB today... up over 20% on 4x avg vol:

http://finance.yahoo.com/q/bc?s=DRUG.OB&t=5d

[jiesen]

DRUG.OB is at .75 today. Looks like it was a good buy at .48.

DRUG.OB is still at 0.75 today, but sales are up more than double this year, and EPS is 0.07 for first half of 2008, compared with 0.02 from last year:

http://biz.yahoo.com/iw/080814/0425428.html

check it out!

[Peter Hansen]

Here is the chart for DRUG.OB

http://bigcharts.marketwatch.com/print/print.asp?sid=117550&symb=drug&time=6&freq=1&compidx=&comp=&ma=&maval=&uf=&lf=2&lf2=4&lf3=1024&type=&size=&country=us&o_symb=&startdate=&enddate=&style=320&backurl=%2Fquickchart%2Fquickchart.asp&prms=qcd&default=false&originalstyle=320&originalurl=%2Fquickchart%2Fquickchart.asp%3Fframe s%3D0%26frames%3D0%26symb%3Ddrug%26unused%3D0%26o_ symb%3Ddrug%26freq%3D1%26time%3D6%26style%3D320%26 default%3Dtrue%26backurl%3D%252Fquickchart%252Fqui ckchart%252Easp%26prms%3Dqcd%26sid%3D117550

NOTICE

1. Last 3 of the 5 trading days are RED or DOWN...so it may go up today!
2. Notice that Volume is very low Not GOOD
3. Relative strength is LOW
4. MACD is set to go negative
5. DMI is negative

Based on the above 5 Points , IMHO , I would NOT buy the stock and this point . Better to buy the entire Biotech Index or XBI .

Now for comparison here is the XBI chart .....the question becomes .....where are ya gonna place your bet...for me the choice is obvious ....look at the sweet XBI chart ......Pete smells money there!

http://bigcharts.marketwatch.com/print/print.asp?sid=2814495&symb=xbi&time=6&freq=1&compidx=&comp=&ma=&maval=&uf=&lf=2&lf2=4&lf3=1024&type=&size=&country=us&o_symb=&startdate=&enddate=&style=320&backurl=%2Fquickchart%2Fquickchart.asp&prms=qcd&default=false&originalstyle=320&originalurl=%2Fquickchart%2Fquickchart.asp%3Fframe s%3D0%26symb%3Dxbi%26unused%3D0%26o_symb%3Dxbi%26f req%3D1%26time%3D6%26x%3D19%26y%3D16%26style%3D320 %26default%3Dtrue%26backurl%3D%252Fquickchart%252F quickchart%252Easp%26prms%3Dqcd%26sid%3D2814495

[jiesen]

Sales, profits are up again at DRUG.OB. Why the stock isn't up yet, I don't know... but I imagine it won't be long before it is!

from:

http://finance.yahoo.com/news/Dragon-Pharma-Reports-2009-iw-3014603751.html?x=0&.v=1


Dragon Pharma Reports 2009 Third Quarter Financial Results

Net Income Increased 108% to $2.20 Million for the Third Quarter

Press Release

Source: Dragon Pharmaceutical Inc.
On 5:00 pm EST, Monday November 16, 2009
VANCOUVER, BRITISH COLUMBIA--(Marketwire - 11/16/09) - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company") (TSX:DDD (http://finance.yahoo.com/q;_ylt=AkxHiSucq.s2D13t9wfaS4Ktcq9_;_ylu=X3oDMTB1b TZycmViBHBvcwMxBHNlYwNuZXdzQXJ0U3RhcnQEc2xrA2RkZA--?s=ddd.to) - News (http://finance.yahoo.com/q/h;_ylt=AjmQcKW2cQbm6fnSagWKU2etcq9_;_ylu=X3oDMTB2M WIxcnJxBHBvcwMyBHNlYwNuZXdzQXJ0U3RhcnQEc2xrA25ld3M-?s=ddd.to))(OTC.BB:DRUG (http://finance.yahoo.com/q;_ylt=AkKRUJkSQ3Nb4ozD8D3LjcGtcq9_;_ylu=X3oDMTB2M GgwMm5vBHBvcwMzBHNlYwNuZXdzQXJ0U3RhcnQEc2xrA2RydWc-?s=drug.ob) - News (http://finance.yahoo.com/q/h;_ylt=AuB1Nm86Pl69Sx23DFjTSIetcq9_;_ylu=X3oDMTB2Z nZiMmFoBHBvcwM0BHNlYwNuZXdzQXJ0U3RhcnQEc2xrA25ld3M-?s=drug.ob))(BBSE: DRP), a leading international pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2009, achieving earnings per share ("EPS") of $0.03 for the quarter and $0.08 for the first nine months of the year.

In Thousand US$ months ended Change months ended Change
(Except EPS) September 30 % September 30 %
------------------------- -------------------------
2009 2008 2009 2008
------------------------- -------------------------
Total Sales 41,497 35,482 +17% 118,601 115,498 +3%
Total Gross Profit 6,479 5,221 +24% 19,737 19,116 +3%
Income from Operations 3,472 907 +283% 10,471 7,643 +37%
Net Income 2,196 1,056 +108% 5,694 5,939 -4%
EPS (Basic and Diluted) 0.03 0.02 +50% 0.08 0.09 -1%


Financial Highlights for the Third Quarter of 2009

Financial Highlights for the Third Quarter of 2009
- Total sales increased 17% to $41.50 million from $35.48 million for the same period of 2008
-- Penicillin Division's sales increased 13% to $11.79 million from $10.42 million
-- Cephalosporin Division's sales increased 19% to $29.70 million from $25.06 million
- Gross profit increased 24% to $6.48 million from $5.22 million for the same period of 2008
- Total operating expenses decreased to $3.01 million from $4.31 million for the same period of 2008
- Net income increased 108% to $2.20 million from $1.06 million for the same period of 2008
- Basic and diluted earnings per share were $0.03 compared to $0.02 for the same period of 2008
Financial Highlights for the Nine Months Ended September 30, 2009
- Total sales increased 3% to $118.60 million from $115.50 million for the same period of 2008
-- Penicillin Division's sales were $39.36 million compared to $35.60 million
-- Cephalosporin Division's sales were $79.24 million compared to $79.90 million
- Gross profit increased 3% to $19.74 million from $19.12 million for the same period of 2008
- Total operating expenses decreased to $9.27 million from $11.47 million for the same period of 2008
- Net income was $5.70 million compared to $5.94 million for the same period of 2008
- Basic and diluted earnings per share were $0.08 compared to $0.09 for the same period of 2008

Results for the Quarter Ended September 30, 2009

Revenues for the quarter ended September 30, 2009 were $41.50 million, representing 17% year-over-year growth and 3% sequential growth. Driven by the strong performance of the Company's core product Clavulanic Acid and Cephalosporin Bulk Drugs, sales in China and in the international market increased 15% and 28%, respectively.
Sales from the Penicillin Division increased 13% from the same quarter of 2008 to $11.79 million, accounting for 28% of the Company's total revenues. As the dominant market leader of Clavulanic Acid in China and one of the largest suppliers to the emerging markets, the Company maintained its strong sales momentum in the quarter and achieved 10% of year-over-year growth in sales of Clavulanic Acid products. Sales volumes increased 18% to 21 tons from 18 tons in the same period of 2008. Gross margin further improved to 42% from 35% in the same period of 2008 primarily due to larger production volumes as well as continued improvements in fermentation technology. In September 2009, a long term contract was signed with a current client to supply 10 tons of Clavulanic Acid every year to its subsidiary in another country of the Middle East. Since the Company's Clavulanic Acid production facility has been running beyond its designed capacity for a while, the Company has started an expansion project to expand capacity to 135 tons a year. Completion of this project is planned for the end of this year.

Sales from the Cephalosporin Division increased 19% to $29.70 million, mostly due to substantial sales growth in Cephalosporin crude bulk drugs. As part of the Company's business strategy to establish vertically integrated product lines covering intermediates, bulk drugs and finished formulation products, three new types of crude bulk Active Pharmaceutical Ingredients (API) were added to the Company's product portfolio including Ceftriaxone, Cefalotin and Cefuroxime crude powders. As a result of the broader product offering, sales revenues from crude bulk drugs increased 98% to $11.53 million while sales volumes increased 229% to 106 tons from 32 tons for the same period of 2008. As larger volumes of 7-ACA were used for in-house downstream applications, sales of 7-ACA decreased 16% to $7.62 million and gross margin decreased to 26% from 31% for the same period of 2008.
Net income was $2.20 million, up 108% year-over-year and 7% sequentially. Earnings per share (basic and diluted) were $0.03 compared to $0.02 for the same period of 2008.

"Our performance in this past quarter reflects the quality of our business and our excellent execution as we continued to increase operational and financial efficiency," said Dragon Pharma's Chairman and CEO, Mr. Yanlin Han. "By the end of September, all of our production facilities were operating close to full capacity. In order to maintain our current position in the market, we have taken initiatives to expand our production capacities to the highest possible levels achievable in the existing facilities. Further large scale expansion, however, is not possible in our current location and we may need to work with the city planning authority for a practical solution."

For further information, please refer to the Company's 10-Q, which has been filed with the U.S. Securities and Exchange Commission and the Ontario Securities Commission. The full financial statements are also available on Dragon's website at www.dragonpharma.com (http://us.lrd.yahoo.com/_ylt=AlNBGuhMKNemvt9TQEVXrietcq9_;_ylu=X3oDMTE2c2d pamluBHBvcwMxBHNlYwNuZXdzQXJ0Qm9keQRzbGsDd3d3ZHJhZ 29ucGhh/SIG=11173mb48/**http%3A//www.dragonpharma.com/).

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, incorporated in Florida and headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including Clavulanic Acid and 7-ACA, a key intermediate to produce cephalosporin antibiotics and formulated drugs. Dragon Pharma is the third largest 7-ACA producer and the dominant manufacturer and market leader of Clavulanic Acid products in China. Dragon Pharma utilizes its nationwide sales distribution network, close customer relationships, understanding of local markets and customer needs and low cost structure to outperform its international and domestic peers. With an annual capacity of 780 tons, Dragon Pharma is the largest exporter of 7-ACA in China. To learn more about Dragon Pharmaceutical Inc., please visit www.dragonpharma.com (http://us.lrd.yahoo.com/_ylt=Atks157myTbMNzm..yGcvaitcq9_;_ylu=X3oDMTE2N21 wNHF2BHBvcwMyBHNlYwNuZXdzQXJ0Qm9keQRzbGsDd3d3ZHJhZ 29ucGhh/SIG=11173mb48/**http%3A//www.dragonpharma.com/).

[Websman]

.71??? What a bargain! I might have to buy some next week.